{"entity": "researcher", "timestamp": "2026-08-20T20:50:34.675Z", "family": "Chroma", "given": "Katarina", "initials": "K", "orcid": "0000-0003-0141-0469", "affiliations": ["Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/55906624111848dbaa12cf2f0bb45578.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/55906624111848dbaa12cf2f0bb45578"}}, "publications": [{"entity": "publication", "iuid": "fe9bb4a70ad045b3891d6be0195b1f3f", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/fe9bb4a70ad045b3891d6be0195b1f3f.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/fe9bb4a70ad045b3891d6be0195b1f3f"}}, "title": "Drug-Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics.", "authors": [{"family": "Buchtova", "given": "Tereza", "initials": "T"}, {"family": "Lukac", "given": "David", "initials": "D"}, {"family": "Skrott", "given": "Zdenek", "initials": "Z", "orcid": "0000-0001-6004-3609", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/7c85cd636d3849baad905babd33717c4.json"}}, {"family": "Chroma", "given": "Katarina", "initials": "K", "orcid": "0000-0003-0141-0469", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/55906624111848dbaa12cf2f0bb45578.json"}}, {"family": "Bartek", "given": "Jiri", "initials": "J"}, {"family": "Mistrik", "given": "Martin", "initials": "M", "orcid": "0000-0002-2321-0348", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/9621302bf7dd443eb069a02726b4fa0a.json"}}], "type": "journal article", "published": "2023-02-02", "journal": {"title": "Int J Mol Sci", "issn": "1422-0067", "volume": "24", "issue": "3", "issn-l": null}, "abstract": "Cannabidiol (CBD) is an easily accessible and affordable Marijuana (Cannabis sativa L.) plant derivative with an extensive history of medical use spanning thousands of years. Interest in the therapeutic potential of CBD has increased in recent years, including its anti-tumour properties in various cancer models. In addition to the direct anticancer effects of CBD, preclinical research on numerous cannabinoids, including CBD, has highlighted their potential use in: (i) attenuating chemotherapy-induced adverse effects and (ii) enhancing the efficacy of some anticancer drugs. Therefore, CBD is gaining popularity as a supportive therapy during cancer treatment, often in combination with standard-of-care cancer chemotherapeutics. However, CBD is a biologically active substance that modulates various cellular targets, thereby possibly resulting in unpredictable outcomes, especially in combinations with other medications and therapeutic modalities. In this review, we summarize the current knowledge of CBD interactions with selected anticancer chemotherapeutics, discuss the emerging mechanistic basis for the observed biological effects, and highlight both the potential benefits and risks of such combined treatments. Apart from the experimental and preclinical results, we also indicate the planned or ongoing clinical trials aiming to evaluate the impact of CBD combinations in oncology. The results of these and future trials are essential to provide better guidance for oncologists to judge the benefit-versus-risk ratio of these exciting treatment strategies. We hope that our present overview of this rapidly advancing field of biomedicine will inspire more preclinical and clinical studies to further our understanding of the underlying biology and optimize the benefits for cancer patients.", "doi": "10.3390/ijms24032885", "pmid": "36769206", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC9917508"}, {"db": "pii", "key": "ijms24032885"}], "notes": [], "created": "2026-08-20T13:41:36.416Z", "modified": "2026-08-20T13:41:36.509Z"}, {"entity": "publication", "iuid": "8d0069a022ae479ba89113f9e1432aef", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/8d0069a022ae479ba89113f9e1432aef.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/8d0069a022ae479ba89113f9e1432aef"}}, "title": "A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment.", "authors": [{"family": "Chroma", "given": "Katarina", "initials": "K", "orcid": "0000-0003-0141-0469", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/55906624111848dbaa12cf2f0bb45578.json"}}, {"family": "Skrott", "given": "Zdenek", "initials": "Z", "orcid": "0000-0001-6004-3609", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/7c85cd636d3849baad905babd33717c4.json"}}, {"family": "Gursky", "given": "Jan", "initials": "J"}, {"family": "Bacovsky", "given": "Jaroslav", "initials": "J"}, {"family": "Moudry", "given": "Pavel", "initials": "P", "orcid": "0000-0002-1479-007X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/47775ea18d0b46698afefcbd0c18e382.json"}}, {"family": "Buchtova", "given": "Tereza", "initials": "T", "orcid": "0000-0001-5233-1504", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/1b56b38daf3244dfb97205b7424c6e5d.json"}}, {"family": "Mistrik", "given": "Martin", "initials": "M", "orcid": "0000-0002-2321-0348", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/9621302bf7dd443eb069a02726b4fa0a.json"}}, {"family": "Bartek", "given": "Jiri", "initials": "J", "orcid": "0000-0003-2013-7525", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/288939950c0c4c6393d35c84e5128b5f.json"}}], "type": "journal article", "published": "2022-03-04", "journal": {"title": "Cell Death Dis", "issn": "2041-4889", "volume": "13", "issue": "3", "pages": "203", "issn-l": "2041-4889"}, "abstract": "Despite several approved therapeutic modalities, multiple myeloma (MM) remains an incurable blood malignancy and only a small fraction of patients achieves prolonged disease control. The common anti-MM treatment targets proteasome with specific inhibitors (PI). The resulting interference with protein degradation is particularly toxic to MM cells as they typically accumulate large amounts of toxic proteins. However, MM cells often acquire resistance to PIs through aberrant expression or mutations of proteasome subunits such as PSMB5, resulting in disease recurrence and further treatment failure. Here we propose CuET-a proteasome-like inhibitor agent that is spontaneously formed in-vivo and in-vitro from the approved alcohol-abuse drug disulfiram (DSF), as a readily available treatment effective against diverse resistant forms of MM. We show that CuET efficiently kills also resistant MM cells adapted to proliferate under exposure to common anti-myeloma drugs such as bortezomib and carfilzomib used as the first-line therapy, as well as to other experimental drugs targeting protein degradation upstream of the proteasome. Furthermore, CuET can overcome also the adaptation mechanism based on reduced proteasome load, another clinically relevant form of treatment resistance. Data obtained from experimental treatment-resistant cellular models of human MM are further corroborated using rather unique advanced cytotoxicity experiments on myeloma and normal blood cells obtained from fresh patient biopsies including newly diagnosed as well as relapsed and treatment-resistant MM. Overall our findings suggest that disulfiram repurposing particularly if combined with copper supplementation may offer a promising and readily available treatment option for patients suffering from relapsed and/or therapy-resistant multiple myeloma.", "doi": "10.1038/s41419-022-04651-w", "pmid": "35246527", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC8897388"}, {"db": "pii", "key": "10.1038/s41419-022-04651-w"}], "notes": [], "created": "2026-08-20T08:49:46.144Z", "modified": "2026-08-20T08:49:46.275Z"}, {"entity": "publication", "iuid": "4134a7960e15426eaf700cde063c5873", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/4134a7960e15426eaf700cde063c5873.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/4134a7960e15426eaf700cde063c5873"}}, "title": "RNA-interference screen for p53 regulators unveils a role of WDR75 in ribosome biogenesis.", "authors": [{"family": "Moudry", "given": "Pavel", "initials": "P", "orcid": "0000-0002-1479-007X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/47775ea18d0b46698afefcbd0c18e382.json"}}, {"family": "Chroma", "given": "Katarina", "initials": "K", "orcid": "0000-0003-0141-0469", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/55906624111848dbaa12cf2f0bb45578.json"}}, {"family": "Bursac", "given": "Sladana", "initials": "S", "orcid": "0000-0002-6478-3409", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/45f5fec28cdb4f5a95256b981184cbf8.json"}}, {"family": "Volarevic", "given": "Sinisa", "initials": "S", "orcid": "0000-0003-4893-389X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/579f4a09aa1c493c88f91beb1048184f.json"}}, {"family": "Bartek", "given": "Jiri", "initials": "J", "orcid": "0000-0003-2013-7525", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/288939950c0c4c6393d35c84e5128b5f.json"}}], "type": "journal article", "published": "2022-03-00", "journal": {"title": "Cell Death Differ.", "issn": "1476-5403", "volume": "29", "issue": "3", "pages": "687-696", "issn-l": "1350-9047"}, "abstract": "Ribosome biogenesis is an essential, energy demanding process whose deregulation has been implicated in cancer, aging, and neurodegeneration. Ribosome biogenesis is therefore under surveillance of pathways including the p53 tumor suppressor. Here, we first performed a high-content siRNA-based screen of 175 human ribosome biogenesis factors, searching for impact on p53. Knock-down of 4 and 35 of these proteins in U2OS cells reduced and increased p53 abundance, respectively, including p53 accumulation after depletion of BYSL, DDX56, and WDR75, the effects of which were validated in several models. Using complementary approaches including subcellular fractionation, we demonstrate that endogenous human WDR75 is a nucleolar protein and immunofluorescence analysis of ectopic GFP-tagged WDR75 shows relocation to nucleolar caps under chemically induced nucleolar stress, along with several canonical nucleolar proteins. Mechanistically, we show that WDR75 is required for pre-rRNA transcription, through supporting the maintenance of physiological levels of RPA194, a key subunit of the RNA polymerase I. Furthermore, WDR75 depletion activated the RPL5/RPL11-dependent p53 stabilization checkpoint, ultimately leading to impaired proliferation and cellular senescence. These findings reveal a crucial positive role of WDR75 in ribosome biogenesis and provide a resource of human ribosomal factors the malfunction of which affects p53.", "doi": "10.1038/s41418-021-00882-0", "pmid": "34611297", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC8901908"}, {"db": "pii", "key": "10.1038/s41418-021-00882-0"}], "notes": [], "created": "2026-08-20T08:49:21.533Z", "modified": "2026-08-20T08:49:21.769Z"}]}